AstraZeneca, M.D. Anderson study cancer chemotherapy effects - Philadelphia Business Journal:

ra-iwinyro.blogspot.com
Scientists at M. D. Anderson in Houstom and AstraZeneca in Wilmingtoh will work together to better understanfd how chemotherapies cause peripheral nerve dysfunctiona that cancause numbness, tingling and severe Such side effects, the organization often limit optimal therapeutic dosing in cancef treatments. The scientists' hope is theirf research will lead to new treatmentds toprevent pain, which would extens the therapeutic value of existingt chemotherapies, and to the developmengt of new chemotherapies with less sever e pain-related side effects. M.D. Anderson and AstraZenecz first established an alliancer in 2006 to accelerate the evaluation and approvapof anti-cancer drugs.
"We hope the insights we gain fromthis [expanded] alliancer will ultimately lead to new treatment optionsd that will improve the quality of life for cancefr patients," said Bob Holland, vice president for neuroscience at AstraZeneca. of Exto n initiated a multicenter phase-II study of its Morab-0090 monoclonal antibody product, in combination with the chemotherapuydrug gemcitabine, as a treatment for patientas with pancreatic cancer. Morphotek expects to enroll up to 152 patientsz in the clinical which is being conducted at clinical centers inNorth America, South America and Europee ...
of Horsham has starte treating patients ina phase-I human safetyg study of NUC B1000, its experimental treatmentr for chronichepatitis B virus infection. The company'ss new drug candidate is an RNA interference-base therapeutics that is designed to turn off a gene associatexd withthe disease. The goal of the study is to enroll 15 patientd atthree U.S. clinical sitess and two sites in EasternEurope ... Blue Bell-based received Food and Drug Administratioh approval to begin testingthe company's lead anti-inflammatorgy compound, VGX-1027, which is being developmenft as a potential treatmenty for rheumatoid arthritis and Type 1 diabetes ...
announcec positive preclinical test results for Trodusquemine as a treatmengfor type-2 diabetes. The Plymouth Meetinvg biopharmaceutical company is already testingg Trodusqueminein phase-I clinical trials as a treatmengt for obesity. Jack Armstrong, Genaera's president and CEO, said the companty has amended its investigational new drug application to pursuew both indicationsand "maximize the therapeutic potential" of the Genaera expects to pursue type-32 diabetes as its lead indication for Trodusqueminwe in phase-II clinical trials ...
of Yardlehy plans to follow up two positiv e midstage testings of its experimental caniner allergydrug Promist-VEL502 with a study this year and a pivotal late-stage test next The product incorporates Velcera's patented Promist drug-delivery syste that allows the drug to be formulatex as a metered dose liquid mist that can be sprayed insid e the oral cavity of a dog's The delivery system avoids the need to get pets to swallow pills or liquids. Dennis Steadman, the company's president and CEO, said Velcer is on track to receive produc t approval for theallergy drug, a major cause of skin irritations, in 2012 ...
Wayne-based receiveds FDA approval to marketthe company's VascuVie Visual Ultrasound System for use with assisted vascular access The product provides physicians with a larg e image display of targeted vessels and surrounding anatomy. The marketingg clearance for VascuViewwas Escalon's thirds FDA approval in the last six weeks.